DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (NASDAQ: DRIO) reported Q4 2025 revenue of $5.2M and full-year 2025 revenue of $22.4M versus $27.0M in 2024, driven by a legacy client nonrenewal after the Twill acquisition.
Key metrics: GAAP gross margin 57%, pipeline $122M, contracted/late-stage ARR $12.9M, cash $26M, and full-year operating expenses down 31% to $49.3M.
DarioHealth (Nasdaq: DRIO) will report fourth quarter and full year 2025 results before the market opens on Thursday, March 19, 2026.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda. A replay will be available through Thursday, April 2, 2026.
DarioHealth (NASDAQ: DRIO) published a peer-reviewed ML study in Frontiers in Digital Health on March 10, 2026, analyzing real-world data from 22,414 adults with type 2 diabetes.
Researchers used generalized linear mixed-effects tree models and found sustained blood glucose improvements linked to higher digital engagement; 12 measurements per month emerged as an actionable threshold for glycemic improvement.
DarioHealth (NASDAQ: DRIO) positions its digital platform to boost real-world outcomes for patients using oral GLP-1 therapies by embedding precision behavioral support at scale. Key facts: 79% of members use Dario's weight management, and oral GLP-1s are projected to capture 25% of the GLP-1 market worth $95B by 2030 per Goldman Sachs. Dario highlights medication adherence tools, a grocery scanner and human coaches to reduce dose-timing drift, manage side effects and improve persistence for payers and employers.
DarioHealth (NASDAQ: DRIO) announced it has surpassed 100 peer-reviewed studies and conference abstracts as of Jan 21, 2026, reinforcing its evidence base for employers, health plans and members.
The research portfolio includes large study populations, longitudinal designs (some up to two years), independent third-party investigator-initiated studies, and directly observed outcomes such as actual claims reduction and measured HbA1c improvement. Dario says the body of work positions it among the most evidence-based digital health vendors and supports value-based purchasing and vendor consolidation decisions.
Dario Health (NASDAQ: DRIO) launched DarioIQ™, a new conversational AI layer in the Dario Health app, rolling out a direct-to-consumer first version on Dec 10, 2025 to an opt-in cohort of hypertension members.
DarioIQ™ integrates behavioral insights, real-time biometric interpretation, device connectivity and human coaching across three components — Advisor, Sentinel and Strategist — and builds on the company’s proprietary AI models and 13 billion real-world data points. The company plans staged expansion to employers and health plans and to other chronic pathways including diabetes and weight management, prioritizing safety and clinical validation.
DarioHealth (NASDAQ: DRIO) announced a peer-reviewed JMIR Cardio study (Dec 4, 2025) showing that data-driven digital nudges from its platform were associated with sustained blood pressure (BP) improvements in real-world users.
Key findings: users with high BP saw a larger monthly systolic BP reduction after three months (B = –2.09; P < .001) versus propensity-matched controls (B = –1.06; P = .007); users with higher lifestyle activity achieved greater reduction (B = –5.27; P < .001). 59% of Dario clients use its cardio-metabolic suite.
DarioHealth (NASDAQ: DRIO) announced 34 new employer clients in the past two weeks, bringing 79 clients signed year-to-date, surpassing its 2025 target of 40 new clients by 98%. The new agreements cover tens of thousands of lives and are expected to start contributing to revenue in Q1 2026. Nearly all new clients selected Dario for integrated cardiometabolic care. The company cites clinical outcomes including a 1.4% eHbA1c reduction, 38% blood pressure reduction by one stage, and 10% average BMI reduction. A recent JMIR real-world study with Sanofi and Symphony Health reported 23% lower hospitalization rates and 26% lower all-cause charges for Dario users versus matched usual-care individuals.
DarioHealth (NASDAQ: DRIO) announced publication of a peer-reviewed retrospective cohort study in Journal of Medical Internet Research showing estimated real-world savings and lower utilization for adults with type 2 diabetes using the Dario digital health platform versus matched usual-care individuals.
Key findings: 23.5% lower inpatient hospitalization rates, 26% lower all-cause healthcare resource utilization charges, and an estimated $5,077 gross medical cost savings per patient per year. The 12-month analysis covered 2,445 Dario users vs 7,334 matched controls and reported shorter lengths of stay, lower 30-day readmissions, and a dose-response link between engagement and fewer inpatient/ER events.
DarioHealth (NASDAQ: DRIO) reported third-quarter 2025 results: Q3 revenue $5.0M versus $7.4M a year earlier and $5.4M in Q2 2025. The company cites a strategic shift from one-time sales to high-margin ARR, reporting 60% GAAP gross margin and ~80% non-GAAP gross margin on its B2B2C channel. Dario added 45 new ARR clients year-to-date, exceeded its 2025 goal, and holds a $69M 2026 pipeline while targeting $12.4M in new business. Cash on hand was $31.9M after a $17.5M private placement; management expects cashflow breakeven in late 2026–early 2027.